Vaccine Technology VII

An ECI Continuing Series

June 17-22, 2018
Fairmont Tremblant
Mont Tremblant, Quebec, Canada

Mont-Tremblant, Quebec, Canada

Call for Abstracts!                   Mark Your Calendar!

Request for Next Mailing

Please forward this link to colleagues who may be interested in the conference topic.

About This Conference

Building on the strong momentum established at the Vaccine I-VI meetings, our goal is to gather key leaders in the field to discuss progress and technological challenges facing vaccine development and manufacturing for global needs.

The meeting is organized by scientists from academia and industry in an intimate setting, and differentiates itself from commercial conferences by providing very high quality, cutting-edge scientific content.  This format is an outstanding opportunity for exchange of ideas among scientists from diverse backgrounds and with a representation from different regions of the world.  Many national and international organizations including The Bill and Melinda Gates Foundation as well as the vaccine industry have supported the previous meetings in this series.  We will frequently update our website to inform about confirmed speakers, workshops, abstract submission and registration information.

We are developing a strong scientific program, the draft of which will be available shortly.  Following the input from our Scientific Committee, we will organize keynote talks and technical sessions around current and upcoming major issues in vaccine technology.

We invite anyone interested in this conference and in the advancement of vaccine technologies to better deliver vaccines where needed to contact one of the co-chairs of the conference.

Amine Kamen   amine.kamen@mcgill.ca
Charles Lutsch   Charles.Lutsch@Sanofi.com
Nathalie Garcon   Nathalie.garcon@bioaster.org
Tarit Mukhopadhyay   t.mukhopadhyay@ucl.ac.uk

Preliminary program – Oral Session Descriptions

Session I and session II. Technological and Clinical Advances in Vaccinology

Our quickly growing understanding of both the immune system and the molecular biology of pathogens, pathogenesis and risk factors, all enable new strategies for prevention and treatment. New vectors, synthetic biology, and specific immune modulation are examples that will play prominent roles for the vaccinology of the 21st century. Bringing forward novel vaccines requires innovative antigen design and presentation. Example classes of innovation include polypeptide, virus-like particle, viral vector and nucleic acid based strategies to elicit protective and targeted humoral and cell based responses using either recombinant or synthetic modes of production.

These sessions encourage examples of recent advances in vaccinology that promise to improve efficacy, safety and availability of “next generation” vaccines.

Session III and Session IV. Bioprocessing advances in vaccine manufacturing

This session will consider advances in vaccine process development and manufacturing. This can include breakthroughs in upstream and downstream technologies, whole bioprocessing, process intensification, advances in process analytics, simplification of industrialised processes and process economics. This session will also accept new modes of production that are applied to vaccines, such as integrated and continuous manufacturing as well as impact onto supply chain.

Case studies detailing challenges and their potential solutions are in particular encouraged, especially those that interlink with the immunogenicity and efficacy of vaccines. This session will also welcome testing strategies, licensure case studies, and post-licensure life cycle management.

Session V. Formulation, Analytics and Delivering Vaccines

This session seeks advances in the formulation, analytics and route of administration of vaccines. It encompasses in-depth characterization, such as in vitro and in vivo assays to evaluate the biological, chemical and physical properties of a vaccine, understanding function, potency and toxicity issues, and improvements to efficacy and safety. In addition, bio-analytical characterization plays a critical role in establishing comparability of the product produced with process, scale and site changes.

Topics such as dose sparing, single dose protection, increasing shelf life, and thermostable formulation are sought. Strategies of formulation selection for licensure, to discussing the new emerging delivery technologies that are being brought to the field of vaccines are encouraged.

Session VI. Capacity Building and Intervention Plan for Emerging and Re-emerging Infectious Diseases

Infectious diseases remain a leading cause of global mortality. Outbreaks including SARS, Ebola and Zika reveal major gaps in emergency preparedness. Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) has been created building “on the global consensus that new and sustainable partnership models are needed to develop vaccines, diagnostics, and therapeutics to contain outbreaks of emerging and reemerging infectious diseases. Such partnerships should fill need for coordinated and proactive R&D and increased funding, stronger advanced development and manufacturing capabilities, regulatory innovations and harmonization of regulatory requirements, ” as stated by Prof. J. Arne Røttingen, Interim CEO, CEPI.

This session will provide a forum to experts to highlight case studies on the accelerated development of new vaccines against emerging pathogens, and share views on novel strategies in building capacities to improve preparedness against emerging and reemerging infectious diseases.

Session VII. Therapeutic Vaccines

While cancer vaccines and oncolytics have dominated this space historically, the therapeutic vaccines session seeks to encompass all non-prophylactic vaccines and aspects of their discovery, mode of action, understandings to their mode or protection, development and production. Early clinical data is especially encouraged and new vectors, mechanisms, cell-based therapies, and non-traditional targets, such as diabetes and the development of tolerance models will be welcomed. Patient payment cost and commercialisation models will also be of interest.

Session VIII. One World, One Health

The vast majority of emerging and re-emerging pathogens in humans are of animal origin. Many of these threats have their origin in wildlife, while humans are exposed either directly or indirectly via domestic animal contact. Effective and economical ways of protecting humans from emerging diseases are best based on combatting zoonotic pathogens at the animal source. The “One Health” concept creates awareness of the major opportunities that exist to protect public health through policies aimed at controlling these pathogens at the level of their animal hosts, or more specifically, at the interface between humans, animals and their environments. Implementation of these policies places those who have regular contacts with domestic animals, like owners, handlers and veterinarians, in the front line together with those who regularly come into contact with wildlife and their environment. This session seeks to highlight the importance of the integration between medical and veterinary disciplines within the One Health concept.

Conference Organization

Conference Chairs:

Amine Kamen, McGill University
Tarit Mukhopadhyay, University College London
Nathalie Garcon, Bioaster
Charles Lutsch, Sanofi Pasteur

Scientific Committee

Paula Alves (IBET)
Barry Buckland (BiologicsB)
Fred Cassel (PATH)
Leda Castilho (University of Rio de Janeiro)
Manon Cox (Protein Sciences)
Tony D’Amore (Sanofi-Pasteur)
Martin Friede (WHO)
Francesc Godia (Universitat Autònoma de Barcelona)
Florian Krammer (Icahn School of Medicine at Mount Sinai)
Gary Kobinger (Laval University)
Lakshmi Krishnan, (National Research Council of Canada)
Linda Lua (University of Queensland)
Laura Palomares (UNAM)
Richard Peluso (Merck)
Hari Pujar (Moderna Therapeutics)
Udo Reichl (Max Planck Institute)
David Robinson, Robinson Vaccines and Biologics LLC
Amadou Alpha Sall (Institut Pasteur de Dakar)
Xuefeng Yu (CanSincoBiologics, Inc.)

Abstract Submission

Detailed session descriptions are available in the Preliminary Program above.  Please use these descriptions to pre-select up to two sessions where you believe your work fits best.

Abstracts (one page maximum) that include specific results and conclusions to allow a scientific assessment of the proposed oral presentation are invited.  Please prepared your abstract according to this template: docx or doc.

Abstracts must be submitted electronically using the template provided at: THIS LINK.

Oral abstract submission deadline:                January 28, 2018
Poster abstract submission deadline:            March 30, 2018

Abstracts of all presentations will be made available to conference participants prior to the start of the conference.

Note:  Only a limited number of oral presentation slots are available and thus all submissions for oral sessions will be considered for both oral and poster presentation.

Awards will be presented for the overall best poster and for the top three student posters.

Sponsorship Levels

Please click HERE to view the opportunities for sponsorship.

Conference Venue

The Fairmont Tremblant Hotel, which made its official debut in February 1997, is located at the base of Mont Tremblant in the magnificent Laurentian region of Quebec.  The concept for Fairmont Tremblant hotel originated with the vision of a modern chateau situated in harmony with its natural surroundings and the colorful pedestrian village.  Architects and designers worked together to combine modern conveniences and a warm décor that reflected the mountain life.  The architects drew inspiration from 19th-century Quebec seigneury, whose grant Provencal-style residences dominated the merchant squares overlooking the outskirts of the village.

Embedded in the mountainside, the village of Mont Tremblant features French-inspired architecture that evokes the charm of old Quebec City, with pitched rooftops, corrugated shingles, old-fashioned chimneys and a U-shaped design opening onto a public square – a meeting place and public crossroads for the villagers.

18AA rustic fairmont_tremblantChasse-galerie sur le Mont Tremblant, a Quebec legend, tells the tale of a group of lumberjacks desperate to return home to their families after spending months in the Laurentian forests.  Visited one night by a mysterious stranger with a flying canoe, they boarded the craft and he expelled an enchanted command creating colorful sparks that propelled the canoe into the air.  As they passed over Mont Tremblant, they slowed their rhythm and lit a lantern to light up the night.  This inspired Fairmont Tremblant hotel’s rustic interior design.

Fairmont Tremblant, 3025 Chemin de la Chapelle, Mont Tremblant, Quebec, Canada

Canadian Visa Information

General Information about ECI

Engineering Conferences International (ECI) is a global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

The format of the weeklong research conference provides morning and late afternoon or evening sessions in which major presentations are made. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe that the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.

All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.

Engineering Conferences International
32 Broadway, Suite 314, New York, NY 10004
T: 1-7212-514-6760 – F: 1-212-514-6030

info@engconfintl.orgwww.engconfintl.org